FDA Gets Green Light For Risk-Benefit Analysis From Ephedra Ruling
This article was originally published in The Tan Sheet
Executive Summary
An appellate court decision upholding FDA's ban of ephedra "will embolden FDA to challenge products that have a bad safety profile," according to Scott Bass, a food and drug law expert and partner at Sidley Austin (Washington, DC)